Section Arrow
Quote
BMRN.NASDAQ
- BioMarin Pharmaceutical
Quotes are at least 15-min delayed:2024/05/16 09:24 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
80.4 
1-M High
93.015 
Volume 
-- 
Bid
78.97
Ask
80.98
Day Low
-- 
Open
-- 
1-M Low
79.52 
Market Cap 
15.27B 
Currency USD 
P/E 75.85 
%Yield 0 
10-SMA 81.61 
20-SMA 83.84 
50-SMA 85.81 
52-W High 99.56 
52-W Low 76.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.06/3.45
Enterprise Value
15.86B
Balance Sheet
Book Value Per Share
26.72
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
2.42B
Operating Revenue Per Share
12.17
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%-- 
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%7.98PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed：2024/05/16 09:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.